Made In China

Has any government agency taken action against Made In China over GLP-1 drugs?

Made In China is named in 2 actions in this index: Connecticut Attorney General, settlement agreement, May 6, 2026; Connecticut Attorney General, civil investigative demand (an investigation, not a finding), May 21, 2025. Of the FDA GLP-1 warning letters and openFDA recall reports in this index as of Nov 15, 2026, none is addressed to a firm under this name.

FDA records were matched by exact name only. A firm can appear in FDA records under a different legal name.

Names in the releases
Made In China; Made-in-China
Actions in this index
2
Latest release
May 6, 2026

Records

Release
May 6, 2026Connecticut Attorney GeneralSettlement agreementGLP-1 drugs (no ingredient named for this firm)portal.ct.gov
May 21, 2025Connecticut Attorney GeneralCivil investigative demand (an investigation, not a finding)Semaglutide, Tirzepatideportal.ct.gov

What each release says

Other firms named in the same releases are listed on the enforcement page.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.